Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma [2]

Blood

Volumn 101, Issue 3, 2003, Pages 1201-1202

  Laterveer, Laurens ^a   Verdonck, Leo F ^a   Peeters, Ton ^a   Borst, Erik ^a   Bloem, Andries C ^a   Lokhorst, Henk M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

BONE MARROW TRANSPLANTATION; CASE REPORT; CELL INFILTRATION; CHROMOSOME 13; CLINICAL FEATURE; DISEASE COURSE; FEMALE; GENE DELETION; GRAFT VERSUS HOST REACTION; HUMAN; LABELING INDEX; LETTER; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0037310491     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2977     Document Type: Letter

References (9)

1. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Intergroupe Francophone du Myelome. Blood. 2001;97:1566-1571.
2. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925-1930.
3. Konigsberg R, Zojer N, Ackermann J, et al. J Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000 Feb;18:804-812.
4. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
5. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3017.
6. Lokhorst HM, Sonneveld P, Cornelissen JJ, et al. et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and (IDM) intermediate-dose melphalan followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant. 1999;23:317-322.
7. Peter Willems, Onno Verhagen, Christine Segeren, et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Blood. 2000;96:63-70.
8. Mielcarek M, Sandmaier BM, Maloney DG, et al. Nonmyeloablative hematopoietic cell transplantation:status quo and future perspectives. J Clin Immunol. 2002;22:70-74.
9. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransiplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-2579.